The present review summarizes up-to-date evidence addressing the frequently discussed clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer patients with viral infections, including AIDS, hepatitis B and C, progressive multifocal leukoencephalopathy, influenza, and COVID-19. In detail, we provide available information on (1) safety regarding the risk of new infections, (2) effects on the outcome of pre-existing infections, (3) whether immunosuppressive drugs used to treat ICI-related adverse events affect the risk of infection or virulence of pre-existing infections, (4) whether the use of vaccines in ICI-treated patients is considered safe, and (5) whether there are beneficial effects of ICIs that even qualify them as a therapeutic approach for these viral infections.
【저자키워드】 review, vaccination, T-lymphocytes, immune evation, tumor escape, 【초록키워드】 COVID-19, Vaccine, Influenza, risk, outcome, viral infections, infections, AIDS, adverse event, Patient, Immune checkpoint inhibitor, hepatitis B, information, virulence, Evidence, Therapeutic approach, risk of infection, Safe, cancer patient, leukoencephalopathy, treat, Effect, Affect, immunosuppressive drug, 【제목키워드】 COVID-19, viral infection, Patient, Immune checkpoint inhibitor,